The Emerging Landscape of Pneumococcal Vaccines: Serotype Replacement, Capsular Polysaccharides, and Next-Generation Approaches for Vaccine Design

Although pneumococcal conjugate vaccines have markedly reduced the incidence rate of Streptococcus pneumoniae infections, the bacterium still remains a predominant cause of pneumonia, sepsis, meningitis, and otitis media worldwide. Its persistence could be largely attributed to serotype replacement and the emergence of multidrug resistance. S. pneumoniae has more than 100 distinct serotypes, but the available vaccines protect against a limited subset, where uncovered nonvaccine serotypes continue to inflict high mortality and comorbidities especially in children and the elderly. This article has elucidated the role of capsular polysaccharide as the principal determinant of virulence and described its properties including distinct composition, structure, charge, and thickness. It further elaborated how these properties influence the immunogenicity of different serotypes and contribute to their underlying pathophysiology. On the one hand, the negative charge of capsular polysaccharides prevents complement protein-mediated opsonization, and on the other hand, bacteria can dynamically control capsule thickness, balancing immune evasion with colonization. Due to such properties, capsular polysaccharides have been widely utilized for vaccine design. Unlike proteins, capsular polysaccharides are not highly immunogenic and, therefore, coupled with various adjuvants and carrier proteins in different conjugate vaccine formulations. Together, this article reviewed the epidemiology of serotypes, structural composition along with immunogenic features of capsular polysaccharides, and conjugate vaccines. Further, novel vaccine strategies, including expansion of the valency of pneumococcal conjugate vaccines, multiepitope vaccine designs, and protein-based constructs, have been elaborated, which represent pivotal steps toward reducing the infection rate of S. pneumoniae.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-18
DOI
https://doi.org/10.1021/acsomega.6c09792
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Emerging Landscape of Pneumococcal Vaccines: Serotype Replacement, Capsular Polysaccharides, and Next-Generation Approaches for Vaccine Design

Yogeshwar Devarakonda, Kirtimaan Syal, Shubham Kumar Sinha, Ajita Rathi et al.
ACS Omega
Pneumonia and Respiratory Infections
article

The Emerging Landscape of Pneumococcal Vaccines: Serotype Replacement, Capsular Polysaccharides, and Next-Generation Approaches for Vaccine Design

Yogeshwar Devarakonda, Kirtimaan Syal, Shubham Kumar Sinha, Ajita Rathi, MVN Janardhan Reddy
article en

Abstract

Although pneumococcal conjugate vaccines have markedly reduced the incidence rate of Streptococcus pneumoniae infections, the bacterium still remains a predominant cause of pneumonia, sepsis, meningitis, and otitis media worldwide. Its persistence could be largely attributed to serotype replacement and the emergence of multidrug resistance. S. pneumoniae has more than 100 distinct serotypes, but the available vaccines protect against a limited subset, where uncovered nonvaccine serotypes continue to inflict high mortality and comorbidities especially in children and the elderly. This article has elucidated the role of capsular polysaccharide as the principal determinant of virulence and described its properties including distinct composition, structure, charge, and thickness. It further elaborated how these properties influence the immunogenicity of different serotypes and contribute to their underlying pathophysiology. On the one hand, the negative charge of capsular polysaccharides prevents complement protein-mediated opsonization, and on the other hand, bacteria can dynamically control capsule thickness, balancing immune evasion with colonization. Due to such properties, capsular polysaccharides have been widely utilized for vaccine design. Unlike proteins, capsular polysaccharides are not highly immunogenic and, therefore, coupled with various adjuvants and carrier proteins in different conjugate vaccine formulations. Together, this article reviewed the epidemiology of serotypes, structural composition along with immunogenic features of capsular polysaccharides, and conjugate vaccines. Further, novel vaccine strategies, including expansion of the valency of pneumococcal conjugate vaccines, multiepitope vaccine designs, and protein-based constructs, have been elaborated, which represent pivotal steps toward reducing the infection rate of S. pneumoniae.

ACS Omega
Birla Institute of Technology and Science - Hyderabad Campus (IN), Birla Institute of Technology and Science, Pilani (IN)
National Research Foundation, Department of Biotechnology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India, University Grants Commission, Birla Institute of Technology and Science, Pilani, Science and Engineering Research Board
Good health and well-being
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon